Elanco Animal Health Incorporated
(NYSE: ELAN)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Elanco Animal Health Incorporated (“Elanco” or the “Company”) on behalf of stockholders.
The investigation cover stockholders who purchased or otherwise acquired Elanco shares on or before November 7, 2023 and continue to hold their shares.
ABOUT THE INVESTIGATION:
The investigation concerns whether Elanco and certain of its directors and/or officers issued materially misleading information and/or failed to disclose material information to the investing public. Specifically, the investigation concerns whether Elanco and certain of its directors and/or officers failed to disclose to shareholders, among other things, that: (i) one of the Company’s proprietary products, Zenrelia, was less safe than the Company claimed; (ii) Elanco was unlikely to meet its previously-announced timeline for U.S. approval and commercial launch of Zenrelia and Credelio Quattro, ; and (iii) as a result, the Company’s business and/or financial prospects were overstated.
THERE IS NO COST TO YOU.
There is no cost to you to join this action. We represent investors on a contingency fee basis. This means that we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees only if we are successful.
If you are interested in joining the action or receiving more information, you may fill out the form below or contact Leah Wihtelin cost free at (516) 693-8926 or by email at lw@rl-legal.com.
